Treatment outcomes following continuous miglustat therapy in
Por um escritor misterioso
Last updated 31 maio 2024
Background Niemann-Pick disease Type C (NP-C) is a rare, progressive neurodegenerative disorder characterized by progressive neurodegeneration and premature death. We report data at closure of the NPC Registry that describes the natural history, disease course and treatment experience of NP-C patients in a real-world setting. Methods The NPC Registry was a prospective observational cohort study that ran between September 2009 and October 2017. Patients with a confirmed diagnosis of NP-C were enrolled regardless of treatment status. All patients underwent clinical assessments and medical care as determined by their physicians; data were collected through a secure internet-based portal. Results At closure on October 19, 2017, 472 patients from 22 countries were enrolled in the NPC Registry. Mean (standard deviation) age at enrollment was 21.2 (15.0) years, and 51.9% of patients were male. First neurological symptom onset occurred during the early-infantile (< 2 years), late-infantile (2 to < 6 years), juvenile (6 to < 15 years), or adolescent/adult (≥ 15 years) periods in 13.5, 25.6, 31.8, and 29.1% of cases, respectively. The most frequent neurological manifestations prior to enrollment included ataxia (67.9%), vertical supranuclear gaze palsy (67.4%), dysarthria (64.7%), cognitive impairment (62.7%), dysphagia (49.1%), and dystonia (40.2%). During infancy, splenomegaly and hepatomegaly were frequent (n = 199/398 [50%] and n = 147/397 [37.0%], respectively) and persisted in most affected patients. Of the 472 enrolled patients, 241 were continuously treated with miglustat during the NPC Registry observation period, of whom 172 of these 241 patients were treated continuously for ≥12 months. A composite disability score that assesses impairment of ambulation, manipulation, language, and swallowing was highest in the early-infantile population and lowest in the adolescent/adult population. Among the continuous miglustat therapy population, 70.5% of patients had improved or had stable disease (at least 3 of the 4 domains having a decreased or unchanged score between enrollment and last follow-up). The NPC Registry did not identify any new safety signals associated with miglustat therapy. Conclusions The profiles of clinical manifestations in the final NPC Registry dataset agreed with previous clinical descriptions. Miglustat therapy was associated with a stabilization of neurological manifestations in most patients. The safety and tolerability of miglustat therapy was consistent with previous reports.
Frontiers Therapeutic Strategies For Tay-Sachs Disease
EP2796457A1 - Genz 112638 for treating Gaucher or Fabry disease in
Therapeutic advantages of combined gene/cell therapy strategies in
Long term follow-up to evaluate the efficacy of miglustat
Opfolda: Package Insert
Randomized, controlled trial of miglustat in Gaucher's disease
Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized
Recommendations for oral treatment for adult patients with type 1
PDF] Miglustat for treatment of Niemann-Pick C disease: a
Full article: New therapies in the management of Niemann-Pick type
Treatment outcomes following continuous miglustat therapy in
CNS-accessible Inhibitor of Glucosylceramide Synthase for
Recomendado para você
-
IJMS, Free Full-Text31 maio 2024
-
Two-Year-Old Kamryn Living with Niemann-Pick Disease Type C (NPC) - The Children's Inn at NIH31 maio 2024
-
NNPDF on X: October is Global Niemann-Pick Disease Awareness Month! For more information on Niemann-Pick Disease or to make a donation to NNPDF go to #niemannpick #ASMD #NPC #raredisease #NNPDF #NiemannPickC31 maio 2024
-
Niemann Pick disease31 maio 2024
-
Niemann-Pick disease: Darlington man's charity walk plan raises31 maio 2024
-
Niemann-Pick Diseases - The Medical Biochemistry Page31 maio 2024
-
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological31 maio 2024
-
The Neuropsychiatry of Niemann-Pick Type C Disease in Adulthood31 maio 2024
-
High Yielding Shorts-111 (#HYS-111):Niemann-Pick Disease Dr Devesh31 maio 2024
-
Niemann-Pick Disease - Types, Causes, Symptoms, Diagnosis & Treatment31 maio 2024
você pode gostar
-
Como fazer o download do Discord, plataforma de chat para gamers31 maio 2024
-
Skate Cartões de jogo31 maio 2024
-
Callipygian Definition Print - Israel31 maio 2024
-
How To Download Games While The Xbox Series X31 maio 2024
-
Naruto Clássico e Shippuden dublados entram para o catálogo da31 maio 2024
-
Phoenix Wright: Ace Attorney Trilogy (2014) Preview - Relive The Titular Defense Attorney's Beginnings This Winter - Game Informer31 maio 2024
-
Saiba quais são os jogos da Copa do Mundo de hoje, segunda-feira31 maio 2024
-
Kei Karuizawa Classroom of the Elite R Goddess Story Card Anime31 maio 2024
-
Fato de cão de São Bernardo para criança - Venca - MKP00002128731 maio 2024
-
BF4DB31 maio 2024